leadf
logo-loader
viewSensyne Health PLC

Sensyne Health announces US launch of product that remotely monitors for diabetes in pregnancy

The group's partner Cognizant will oversee the roll-out of GDm-Health across the Atlantic

Sensyne Health PLC -

Sensyne Health PLC (LON:SENS) has announced the US launch of a product that remotely monitors for diabetes in pregnancy.

The group said its partner Cognizant will oversee the roll-out of GDm-Health, which will qualify for reimbursement under remote patient monitoring codes introduced by the Centers for Medicare and Medicaid Services.

Diabetes in pregnancy is a common condition that can increase the risk of hypertension and caesarean section in mothers as well as pre-term birth, birth trauma and admission to neonatal intensive care for new-born babies.

Over 20% of pregnancies in the States are affected by diabetes every year.

GDm-Health has the potential to significantly improve the way this treatable condition is managed.

The push into the US follows results from a trial in the UK that demonstrated a reduction in caesarean sections, improvements in blood glucose monitoring adherence and higher satisfaction with care in women using the Sensyne device.

The company is currently wrapping up a pilot of the technology at Jefferson Health, a network of 14 hospitals in the Greater Philadelphia area.

Results are expected to be reported in a peer-reviewed journal early next year.

Sensyne chief executive Lord Drayson said the GDm-Health’s American launch marked a “major milestone” and “key objective” for the financial year.

“Entering the US market will help pregnant women and clinicians in the US manage diabetes in pregnancy, improving outcomes for both mothers and babies,” he added in a statement.

Quick facts: Sensyne Health PLC

Price: 164.5 GBX

AIM:SENS
Market: AIM
Market Cap: £261.69 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sensyne Health PLC named herein, including the promotion by the Company of Sensyne Health PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Sensyne Health collaborate with Excalibur for lateral flow rapid COVID-19...

Sensyne Health PLC's (LON:SENS) Chief Executive Lord Paul Drayson talks to Proactive London's Katie Pilbeam about their latest 'breakthrough deal' with Excalibur.  The firm has signed a COVID-19 test partnership as part of an exclusive licence and development agreement with Excalibur...

2 weeks, 3 days ago

2 min read